Labetalol

Generic Name: Labetalol

Brand Names: Trandate

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₄N_₂O_₃

CAS Number: 36894-69-6

Unique Ingredient Identifier: R5H8897N95

Background: Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.

Labetalol was granted FDA approval on 1 August 1984.

Indication: Labetalol injections are indicated to control blood pressure in severe hypertension. Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.

Associated Conditions: Chronic Stable Angina Pectoris, Hypertension, Hypertensive Emergency, Hypertensive crisis, Pheochromocytoma, Subarachnoid Hemorrhage

Associated Therapies: -

Clinical Trials

Blood Pressure After Endovascular Stroke Therapy-II

Phase 2

Completed

Conditions: Endovascular Thrombectomy
Acute Stroke

Interventions: Drug: Nicardipine
Drug: Labetalol
Drug: Hydralazine

First Posted Date: 2019-10-04

Last Posted Date: 2023-10-12

Lead Sponsor: University of Cincinnati

Target Recruit Count: 120

Registration Number: NCT04116112

Locations: 🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension

Phase 4

Completed

Conditions: Sinus Endoscopic Surgery
Deliberate Hypotension
Tissue Perfusion

Interventions: Drug: Nitroglycerin
Drug: Labetalol

First Posted Date: 2019-01-18

Last Posted Date: 2020-04-27

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT03809065

Locations: 🇪🇬
Kasr Al Ainy, Cairo, Egypt

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

Phase 2

Completed

Conditions: Chronic Sinusitis

Interventions: Drug: Esmolol
Drug: Labetalol

First Posted Date: 2018-09-07

Last Posted Date: 2021-02-08

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 28

Registration Number: NCT03661346

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

First Posted Date: 2018-04-27

Last Posted Date: 2024-12-17

Lead Sponsor: Duke University

Target Recruit Count: 1600

Registration Number: NCT03511118

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Loma Linda University Health, Loma Linda, California, United States

and more 19 locations

Response to Anti-hypertensives in Pregnant and Postpartum Patients

Phase 4

Completed

Conditions: Hypertension in Pregnancy
Preeclampsia

Interventions: Drug: Nifedipine
Drug: Labetalol

First Posted Date: 2018-04-24

Last Posted Date: 2021-05-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 109

Registration Number: NCT03506724

Locations: 🇺🇸
Maimonides Hospital, Brooklyn, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States

Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia

Phase 2

Conditions: Severe Pre-Eclampsia, Antepartum

Interventions: Drug: Nifedipine 10 mg
Drug: Labetalol

First Posted Date: 2017-10-30

Last Posted Date: 2017-10-30

Lead Sponsor: Services Institute of Medical Sciences, Pakistan

Target Recruit Count: 194

Registration Number: NCT03325348

Locations: 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan

Effect of Hypotensive Anesthesia on the Perfusion Index

Early Phase 1

Completed

Conditions: Controlled Hypotension for Nasal Surgeries

Interventions: Combination Product: Massimo device
Drug: Nitroglycerin drug
Drug: Labetalol

First Posted Date: 2017-02-23

Last Posted Date: 2019-03-29

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT03059316

The Effect of Intraoperative Labetalol on Time to Discharge

Phase 2

Completed

Conditions: Heart Rate
Bloodpressure

Interventions: Drug: Esmolol
Drug: Fentanyl
Drug: Labetalol
Other: 1 ml saline infusion
Other: saline infusion

First Posted Date: 2016-12-20

Last Posted Date: 2020-02-13

Lead Sponsor: Dr. Robert Tanzola

Target Recruit Count: 172

Registration Number: NCT02997800

Locations: 🇨🇦
Queen's University, Department of Anesthesiology, Kingston, Ontario, Canada

Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

Not Applicable

Withdrawn

Conditions: Hypertension

Interventions: Drug: Hydralazine
Drug: Labetalol
Drug: nifedipine

First Posted Date: 2016-10-14

Last Posted Date: 2017-11-13

Lead Sponsor: St. Louis University

Registration Number: NCT02933593

Early Vascular Adjustments During Hypertensive Pregnancy

Phase 4

Conditions: Hypertension, Pregnancy-Induced
Pre-Eclampsia

Interventions: Drug: Labetalol
Drug: Nifedipine
Drug: Methyldopa

First Posted Date: 2015-08-24

Last Posted Date: 2021-03-24

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 368

Registration Number: NCT02531490

Locations: 🇳🇱
Maastricht UMC, Maastricht, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy